# INVO Fertility, Inc.: financial statements, quarterly

IVF · Nasdaq · CIK 1417926 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ivf.md) · [Financials](/companies/ivf/financials.md) · [Filings](/companies/ivf/filings.md) · [Insiders](/companies/ivf/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ivf/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.0](/filings/0001493152-24-046822.md) | [1.4 d](/filings/0001641172-25-006726.md) | [1.6](/filings/0001641172-25-011710.md) | [1.8](/filings/0001493152-24-046815.md) | [1.4](/filings/0001493152-24-046822.md) | [1.7 d](/filings/0001641172-25-006726.md) | [1.6](/filings/0001641172-25-011710.md) | [1.9](/filings/0001493152-26-038528.md) | [1.8](/filings/0001493152-25-023751.md) | [1.6 d](/filings/0001493152-26-026775.md) | [2.0](/filings/0001493152-26-029514.md) | [2.2](/filings/0001493152-26-038528.md) |
| Cost of revenue | $m | [0.6](/filings/0001493152-24-046822.md) | [0.9 d](/filings/0001641172-25-006726.md) | [0.9](/filings/0001641172-25-011710.md) | [0.9](/filings/0001493152-24-046815.md) | [1.0](/filings/0001493152-24-046822.md) | [1.0 d](/filings/0001641172-25-006726.md) | [1.1](/filings/0001641172-25-011710.md) | [0.0](/filings/0001493152-26-038528.md) | not reported | not reported | [0.0](/filings/0001493152-26-029514.md) | [0.1](/filings/0001493152-26-038528.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [0.0](/filings/0001493152-24-046822.md) | [0.0 d](/filings/0001641172-25-006726.md) | [0.0](/filings/0001641172-25-011710.md) | [0.0 d](/filings/0001641172-25-024212.md) | [0.0 d](/filings/0001493152-25-023751.md) | [0.0 d](/filings/0001493152-26-026775.md) | [0.3](/filings/0001641172-25-011710.md) | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [1.3](/filings/0001493152-24-046822.md) | [1.9 d](/filings/0001641172-25-006726.md) | [1.4](/filings/0001641172-25-011710.md) | [2.6](/filings/0001641172-25-024212.md) | [1.5](/filings/0001493152-25-023751.md) | [2.5 d](/filings/0001493152-26-026775.md) | [1.6](/filings/0001493152-26-029514.md) | [2.2](/filings/0001493152-26-038528.md) | [2.1](/filings/0001493152-25-023751.md) | [1.8 d](/filings/0001493152-26-026775.md) | [2.2](/filings/0001493152-26-029514.md) | [1.9](/filings/0001493152-26-038528.md) |
| Operating income | $m | [(0.9)](/filings/0001493152-24-046822.md) | [(1.5) d](/filings/0001641172-25-006726.md) | [(1.5)](/filings/0001641172-25-011710.md) | [(1.9)](/filings/0001641172-25-024212.md) | [(1.3)](/filings/0001493152-25-023751.md) | [(2.0) d](/filings/0001493152-26-026775.md) | [(1.2)](/filings/0001493152-26-029514.md) | [(3.0)](/filings/0001493152-26-038528.md) | [(1.6)](/filings/0001493152-25-023751.md) | [(1.4) d](/filings/0001493152-26-026775.md) | [(1.6)](/filings/0001493152-26-029514.md) | [(1.3)](/filings/0001493152-26-038528.md) |
| Interest expense | $m | [0.4](/filings/0001493152-23-040488.md) | [0.2 d](/filings/0001641172-25-006726.md) | [(0.2)](/filings/0001641172-25-011710.md) | [0.4](/filings/0001641172-25-024212.md) | [0.3](/filings/0001493152-25-023751.md) | [0.2 d](/filings/0001641172-25-006726.md) | [(0.3)](/filings/0001641172-25-011710.md) | [0.4](/filings/0001493152-26-038528.md) | [0.1](/filings/0001493152-25-023751.md) | [0.6 d](/filings/0001493152-26-026775.md) | [0.2](/filings/0001493152-26-029514.md) | [0.2](/filings/0001493152-26-038528.md) |
| Income tax | $m | [0.0](/filings/0001493152-24-046822.md) | [0.0 d](/filings/0001641172-25-006726.md) | [0.0](/filings/0001641172-25-011710.md) | [0.0 d](/filings/0001641172-25-024212.md) | [0.0](/filings/0001493152-25-023751.md) | [0.1 d](/filings/0001493152-26-026775.md) | [0.0](/filings/0001493152-26-029514.md) | not reported | not reported | not reported | [0.0](/filings/0001493152-26-029514.md) | [0.1](/filings/0001493152-26-038528.md) |
| Net income | $m | [(1.2)](/filings/0001493152-24-046822.md) | [(2.0) d](/filings/0001641172-25-006726.md) | [(1.6)](/filings/0001493152-25-023751.md) | [(2.2)](/filings/0001493152-25-023751.md) | [(1.6)](/filings/0001493152-25-023751.md) | [(3.8) d](/filings/0001493152-26-026775.md) | [(17.4)](/filings/0001493152-26-038528.md) | [(3.6)](/filings/0001493152-26-038528.md) | [(3.4)](/filings/0001493152-26-026775.md) | [1.1 d](/filings/0001493152-26-026775.md) | [(5.5)](/filings/0001493152-26-038528.md) | [0.9](/filings/0001493152-26-038528.md) |
| Diluted EPS | $ per share | [(0.70)](/filings/0001493152-24-046822.md) | not reported | [(7.55)](/filings/0001641172-25-011710.md) | [(22.39)](/filings/0001641172-25-024212.md) | [(15.11)](/filings/0001493152-25-023751.md) | not reported | [(3473.93)](/filings/0001493152-26-029514.md) | [(364.23)](/filings/0001493152-26-038528.md) | [(39.40)](/filings/0001493152-26-026775.md) | not reported | [(3.38)](/filings/0001493152-26-029514.md) | [0.35](/filings/0001493152-26-038528.md) |
| Basic EPS | $ per share | [(0.70)](/filings/0001493152-24-046822.md) | not reported | [(7.55)](/filings/0001641172-25-011710.md) | [(22.39)](/filings/0001641172-25-024212.md) | [(15.11)](/filings/0001493152-25-023751.md) | not reported | [(3473.93)](/filings/0001493152-26-029514.md) | [(364.23)](/filings/0001493152-26-038528.md) | [(39.40)](/filings/0001493152-26-026775.md) | not reported | [(3.38)](/filings/0001493152-26-029514.md) | [0.42](/filings/0001493152-26-038528.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue, us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.1](/filings/0001493152-23-040488.md) | [0.2](/filings/0001641172-25-006726.md) | [0.5](/filings/0001493152-24-019786.md) | [0.9](/filings/0001641172-25-024212.md) | [0.5](/filings/0001493152-25-023751.md) | [0.6](/filings/0001493152-26-026775.md) | [0.8](/filings/0001641172-25-011710.md) | [0.5](/filings/0001641172-25-024212.md) | [0.4](/filings/0001493152-25-023751.md) | [2.1](/filings/0001493152-26-038528.md) | [4.9](/filings/0001493152-26-029514.md) | [3.7](/filings/0001493152-26-038528.md) |
| Current assets | $m | [1.8](/filings/0001493152-23-040488.md) | [1.3](/filings/0001641172-25-006726.md) | [1.7](/filings/0001493152-24-019786.md) | [2.4](/filings/0001493152-24-046815.md) | [2.0](/filings/0001493152-24-046822.md) | [1.3](/filings/0001493152-26-026775.md) | [1.6](/filings/0001641172-25-011710.md) | [1.4](/filings/0001641172-25-024212.md) | [1.1](/filings/0001493152-25-023751.md) | [2.8](/filings/0001493152-26-038528.md) | [5.7](/filings/0001493152-26-029514.md) | [4.6](/filings/0001493152-26-038528.md) |
| Total assets | $m | [17.0](/filings/0001493152-24-046808.md) | [18.5](/filings/0001641172-25-006726.md) | [17.3](/filings/0001493152-24-046815.md) | [17.8](/filings/0001493152-24-046815.md) | [17.0](/filings/0001493152-24-046822.md) | [46.1](/filings/0001493152-26-026775.md) | [31.7](/filings/0001641172-25-011710.md) | [19.3](/filings/0001641172-25-024212.md) | [18.8](/filings/0001493152-25-023751.md) | [20.2](/filings/0001493152-26-038528.md) | [24.7](/filings/0001493152-26-029514.md) | [25.8](/filings/0001493152-26-038528.md) |
| Current liabilities | $m | [4.7](/filings/0001493152-24-046808.md) | [8.0](/filings/0001641172-25-006726.md) | [8.8](/filings/0001493152-24-046815.md) | [8.0](/filings/0001493152-24-046815.md) | [8.7](/filings/0001493152-24-046822.md) | [17.9](/filings/0001493152-26-026775.md) | [18.7](/filings/0001641172-25-011710.md) | [12.1](/filings/0001493152-26-026775.md) | [9.1](/filings/0001493152-26-026775.md) | [10.3](/filings/0001493152-26-038528.md) | [6.4](/filings/0001493152-26-029514.md) | [6.5](/filings/0001493152-26-038528.md) |
| Total liabilities | $m | [16.7](/filings/0001493152-24-046808.md) | [17.6](/filings/0001641172-25-006726.md) | [17.3](/filings/0001493152-24-046815.md) | [16.4](/filings/0001493152-24-046815.md) | [17.0](/filings/0001493152-24-046822.md) | [26.0](/filings/0001493152-26-026775.md) | [24.4](/filings/0001641172-25-011710.md) | [16.2](/filings/0001493152-26-026775.md) | [13.0](/filings/0001493152-26-026775.md) | [13.0](/filings/0001493152-26-038528.md) | [9.6](/filings/0001493152-26-029514.md) | [9.3](/filings/0001493152-26-038528.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [1.1](/filings/0001493152-26-026775.md) | not reported | [1.0](/filings/0001641172-25-024212.md) | [1.0](/filings/0001493152-25-023751.md) | [0.7](/filings/0001493152-26-038528.md) | [0.7](/filings/0001493152-26-029514.md) | [0.5](/filings/0001493152-26-038528.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [6.3](/filings/0001493152-26-026775.md) | not reported | [3.8](/filings/0001641172-25-024212.md) | [1.0](/filings/0001493152-25-023751.md) | [1.3](/filings/0001493152-26-038528.md) | [1.2](/filings/0001493152-26-029514.md) | [1.1](/filings/0001493152-26-038528.md) |
| Shareholders' equity | $m | [0.4](/filings/0001493152-24-046822.md) | [0.9](/filings/0001493152-26-026775.md) | [0.0](/filings/0001493152-25-023751.md) | [1.4](/filings/0001493152-25-023751.md) | [(0.0)](/filings/0001493152-25-023751.md) | [12.6](/filings/0001493152-26-038528.md) | [(27.2)](/filings/0001493152-26-038528.md) | [(7.2)](/filings/0001493152-26-038528.md) | [5.8](/filings/0001493152-26-026775.md) | [7.2](/filings/0001493152-26-038528.md) | [15.0](/filings/0001493152-26-038528.md) | [16.5](/filings/0001493152-26-038528.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,247) d](/filings/0001493152-24-046822.md) | [(715) d](/filings/0001641172-25-006726.md) | [(261)](/filings/0001641172-25-011710.md) | [(1,456) d](/filings/0001641172-25-024212.md) | [(641) d](/filings/0001493152-25-023751.md) | [(617) d](/filings/0001493152-26-026775.md) | [(3,546)](/filings/0001493152-26-029514.md) | [(1,718) d](/filings/0001493152-26-038528.md) | [(1,777) d](/filings/0001493152-25-023751.md) | [25.2 d](/filings/0001493152-26-026775.md) | [(1,917)](/filings/0001493152-26-029514.md) | [(1,101) d](/filings/0001493152-26-038528.md) |
| Capital expenditure | $k | [108 d](/filings/0001493152-24-046822.md) | [75.0 d](/filings/0001641172-25-006726.md) | [49.7](/filings/0001641172-25-011710.md) | [55.1 d](/filings/0001641172-25-024212.md) | [0.0 d](/filings/0001493152-25-023751.md) | [78.9 d](/filings/0001493152-26-026775.md) | [14.7](/filings/0001493152-26-029514.md) | [8.9 d](/filings/0001493152-26-038528.md) | [8.1 d](/filings/0001493152-25-023751.md) | [11.8 d](/filings/0001493152-26-026775.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [608](/filings/0001493152-23-040488.md) | [623](/filings/0001493152-24-019786.md) | [732](/filings/0001493152-24-046815.md) | [1,777](/filings/0001493152-24-046822.md) | [211](/filings/0001641172-25-011710.md) | [100](/filings/0001641172-25-024212.md) | [108](/filings/0001493152-25-023751.md) | [5.0](/filings/0001493152-26-029514.md) | [9.9](/filings/0001493152-26-038528.md) | [3,448](/filings/0001493152-25-023751.md) | [1,638](/filings/0001493152-26-029514.md) | [2,592](/filings/0001493152-26-038528.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 2,506,969 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038528.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.